POPLITEAL SCIATIC NERVE BLOCK FOR DIABETIC FOOT SURGERIES
NCT ID: NCT04903743
Last Updated: 2021-05-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
50 participants
INTERVENTIONAL
2021-01-10
2021-07-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Erector Spinae Plane Block and Ankle and Foot Surgery
NCT05708742
Dose-finding Study: Popliteal Sciatic Nerve Block in Patients Undergoing Diabetic Foot Surgery
NCT04981067
Efficacy of Continuous Sciatic Nerve Block in Diabetic Foot Patients
NCT04212325
Efficacy of Popliteal Block and Bupivacaine Concentration Used for Analgesia in Foot and Ankle Surgery
NCT04294732
Characteristics of Popliteal Sciatic Nerve Block in Patients With and Without Diabetic Neuropathy
NCT02076945
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
group B
28ml of 0.25% bupivacaine and 2ml normal saline
bupivacaine
group B received 28ml of 0.25% bupivacaine and 2ml normal saline
group BM
received 28 ml of 0.25% bupivacaine and 2 ml magnesium sulfate 10%.
bupivacaine
group B received 28ml of 0.25% bupivacaine and 2ml normal saline
magnesium sulfate
group BM received 28 ml of 0.25% bupivacaine and 2 ml magnesium sulfate 10%.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
bupivacaine
group B received 28ml of 0.25% bupivacaine and 2ml normal saline
magnesium sulfate
group BM received 28 ml of 0.25% bupivacaine and 2 ml magnesium sulfate 10%.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* scheduled for diabetic foot surgeries.
Exclusion Criteria
* whose BMI ≥ 35 kg/ m2,
* unable to properly describe postoperative pain to investigator (dementia, delirium, psychiatric and neurological disorders),
* patients with coagulopathy, skin infection at the site of injection,
* preoperative use of opioid or non-steroidal anti-inflammatory drugs,
* allergy or contraindication to studied medication
40 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alexandria University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
rehab zayed
Assisstant Professor of Anesthesia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
rehab Abd Elaziz
Alexandria, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0106292
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.